Novel SupremeTM DES with Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation after DES implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.

Alexandra J. Lansky,Dean J. Kereiakes,Andreas Baumbach,Stephan Windecker,Yasin Hussain,Cody Pietras,Ovidiu Dressler,Ozgu Issever,Michael Curtis,Barry D. Bertolet,James P. Zidar,Pieter C. Smits,Victor Alfonso Jimenez Diaz,Brent T. McLaurin,Sjoerd H. Hofma,Angel Cequier,Nabil Dib,Edouard Benit,Anthony Mathur,David Brogno,Jacques Berland,Joanna Wykrzykowska,Guy N. Piegari,Salvatore Brugaletta,Shigeru Saito,Martin B. Leon

Novel SupremeTM DES with Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation after DES implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.

2021

Background: Accelerated endothelial healing after targeted antiproliferative drug delivery may limit the long-term inflammatory response of drug eluting stents (DES). The novel SupremeTM DES (Supre...

Keywords:

inflammatory response
smooth muscle
Pharmacology
Drug
Drug delivery
Coronary artery disease
Randomized controlled trial
Medicine
Cell growth

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations